| Title       | Fluvastatin increases bone mineral density in postmenopausal women |
|-------------|------------------------------------------------------------------|
| Author(s)   | Gotoh, Mituhiro; Mizuno, Kenji; Ono, Yoshiaki; Takahashi, Michihiko |
| Citation    | Fukushima Journal of Medical Science. 57(1): 19-27               |
| Issue Date  | 2011                                                             |
| URL         | http://ir.fmu.ac.jp/dspace/handle/123456789/280                 |
| Rights      | © 2011 The Fukushima Society of Medical Science                   |
| DOI         | 10.5387/fms.57.19                                                 |
| Text Version| publisher                                                       |
FLUVASTATIN INCREASES BONE MINERAL DENSITY IN POSTMENOPAUSAL WOMEN

MITUHIRO GOTOH1), KENJI MIZUNO2), YOSHIKAI ONO3) and MIKIHIKO TAKAHASHI2)

1)Department of Internal Medicine, Fukushima Rosai Hospital, Iwaki, Japan, 2)Department of Ecology and Clinical Therapeutics, Fukushima Medical University School of Nursing, Fukushima, Japan, 3)Health Care Center, Miyagi Social Insurance Hospital, Sendai, Japan

(Received August 11, 2010, accepted February 3, 2011)

Abstract: Although several studies have reported a lower risk of osteoporotic fracture in hypercholesterolemic patients (WHO IIa) treated with statin, longitudinal studies on the effects of statins on bone are lacking. The aim of the present study was to evaluate bone mineral density (BMD) and bone turnover changes induced by 3-year fluvastatin treatment in postmenopausal women. Twenty-eight consecutive postmenopausal non-diabetic, normotensive hypercholesterolemic women (64.0±3.6 years) were treated for 36 months with 30 mg/day fluvastatin and 28 non-diabetic, normotensive normocholesterolemic age- and body mass index-matched postmenopausal women served as the control subjects. The result revealed a significant increase of the BMD as compared with the level at the base line (p<0.001) in the fluvastatin-treated group, from 6 months on ward after the start treatment. Significant differences of the BMD were found between the controls and fluvastatin-treated group (p<0.001) were at 6, 12, 24 and 36 months after the start of the study. In conclusion our results, although obtained small sample of postmenopausal hypercholesterolemic women, suggest a probable favorable effect of fluvastatin on bone formation and BMD.

Key words: fluvastatin, bone mineral density, osteocalcin, deoxypyridionline, postmenopausal women

INTRODUCTION

Hydroxyl-3-methyl glutaryl coenzme A (HMG-CoA) reductase inhibitor, known as statins, which are well-established cholesterol-lowering agents, have also been shown to have pleiotropic effects, such as anti-inflammatory, antithrombotic, and immunoregulatory actions1). In fact, since Mundy et al. reported favorable effects of statins on bone tissue in rats2), numerous other studies has confirmed such effects in vitro3−5). These studies have also demonstrated that the favorable statins effects of statins on bone are mediated by the enhanced expression of the bone morphologic proteins (BMPs), in particular, of BMP2, induced by this class of drugs, which, in turn, leads to osteoblastic differentiation and bone formation6). In addition, statins also seem to interfere with osteoclastic activity6). In fact, HMG-CoA reductase inhibitors have been demonstrated to induce apoptosis of osteoclasts, similar to the actions reported for bisphosphonates7−9).

The reported actions of bisphosphonate and statins inhibiting different steps of the mevalonate pathway9) lend support to the hypothesis that the statins may have significant effects on the bone metabolism in humans.

In recent years, there has been growing evidence to suggest that statins interfere with exert effort on the bone metabolism. Although some controversial data have been reported10−12), numerous experimental and epidemiological studies have shown that statins decrease the risk of fractures in...
the elderly\textsuperscript{13−17}. In addition to these observational studies on the risk of fracture, the effects of statins on the bone mineral density (BMD)\textsuperscript{18−24} and bone turnover parameters\textsuperscript{25−28} have also been investigated in some previous studies, and some contradictory results have been reported. At present, because of the limited data and lack of prospective studies conducted to evaluate the effects of the statins on bone remodeling, there is no consensus on the effects of stains on the makers of bone turnover and the BMD\textsuperscript{29−31}.

Although type 1 diabetes mellitus has been reported to be associated with a decrease of BMD\textsuperscript{32}, reports on the status of the BMD in type 2 diabetes mellitus are conflicting\textsuperscript{33}. We observed that hypertension might be associated with reduced BMD in female essential hypertension\textsuperscript{34}.

The present prospective study was aimed of evaluating the effect of 3-year treatment with fluvastatin at 30 mg/day on the BMD and bone turnover in non-diabetic, normotensive and postmenopausal hypercholesterolemic women.

**SUBJECTS AND METHODS**

**Subjects**

Twenty-eight non-diabetic, normotensive and consecutive postmenopausal hypercholesterolemic women (mean±SD, age: 64.0±3.6 years; range 57–71 years) and 28 healthy postmenopausal women of complete physical examination matched for age, body mass index (BMI) and spine BMD with a T-score of −1 to −2.5 SD in any region (mean±SD, age: 64.0±3.6; range 57–70 years) were recruited. Only subjects with hypercholesterolemia, (≥220 mg/dl, WHO IIa) who had not been treated previously for dyslipidemia were included in the study. In addition, patients were not included in the study if they had receiving any lipid lowering drugs (estrogens, calcitonin, bisphosphonates, anabolic steroids, vitamin D, or drugs known to interfere with bone metabolism) during the previous 6 months or who had amenorrhea for less than 12 months were excluded from the study. Patients with other health problems which could interfere with the conduct of the study were also excluded.

Standard renal, liver, and thyroid function tests were performed before the start of statin therapy, to exclude secondary hypercholesterolemia. Serum creatine kinase was measured to detect any possible side effects of the statin on the muscle tissue.

Hypertension was defined as a systolic blood pressure ≥140 mmHg and/or a diastolic blood pressure ≥90 mmHg\textsuperscript{35} in the sitting position on at least three different occasions. The diagnosis of diabetes mellitus was based on a 75-g oral glucose tolerance test\textsuperscript{36}; individuals were labeled at having diabetes mellitus if the fasting plasma glucose level was 126 mg/dl or the plasma glucose level at 2 h after glucose administration was 200 mg/dl or greater. Patients with hypertension and diabetes mellitus were excluded from the study.

A detail medical history was obtained from all the subjects and the dietary calcium intake was assessed using a validated questionnaire to detect the amount of intake of foods that are known to account for the majority of the calcium in the diet.

During the study period, none of the patients received any treatment that could potentially affect bone metabolism, such as estrogen, calcitonin, bisphosphonates, or calcium and vitamin D supplements.

**Study design**

The 28 non-diabetic, normotensive hypercholesterolemic women selected according to the above-mentioned criteria were administrated fluvastatin at the dosage of 30 mg/day for 36 month and 28 healthy age-, body mass index-matched postmenopausal women served as the control group. It was ensured that the daily dietary calcium intake was about 700 mg the study period in all the study subjects (both hypercholesterolemic patients and control subjects).

In all subjects, fasting venous blood samples were drawn at baseline and at 3-month intervals up to 36 months of fluvastatin treatment in order to determine the serum levels of total cholesterol (TC), high-, low-density and non-high-density lipoprotein cholesterol (HDL-C, LDL-C and non-HDL-C, respectively), triglycerides (TG), serum calcium (Ca), serum inorganic phosphate (iP).

**Measurements**

The lipid parameters, Ca and iP were measured with a Model 7250 autoanalyzer (Hitachi Co., Ltd., Tokyo, Japan). The LDL-C were calculated from TC, TG and HDL-C by using the formula proposed by Friedwald: $\text{LDL-C} = \text{TC} - \left(\text{HDL-C} + \frac{\text{TG}}{5}\right)$. The non-HDL-C were calculated from TC and HDL-C: $\text{TC} - \text{HDL-C}$. The serum levels of intact PTH and osteocalcin were measured by chemiluminescent immunoassay (Nichols Institute Diagnosis SanClement, USA). Serum osteocalcin (OC) was assayed by an immunoradiometric assay (Mitsubishi
Kagaku Iatron, Inc., Tokyo, Japan). Urinary deoxypyridinoline (u-DPD) was determined by an enzyme immunoassay (Quidel Corporation, San Diego, USA).

In all subjects, the BMD was assessed in the lumbar supine (using the central portion of the lateral scout view of the L2-4 vertebrae) by dual energy X-ray absorptiometry (DXA) using a Hologic QDR 2000 (Bedford, USA, at baseline and at 6, 12, 24 and 36 months after the start of the study).

The study was approved by the Ethics Committee of Fukushima Rosai Hospital. All patients and control subjects provided informed written consent to participate in the study.

All of the 28 patients treated with 30 mg of fluvastatin and 28 subjects of the control group completed the 3-year study period.

**Statistical analysis**

Values are expressed as the mean±SD, unless otherwise specified. Statistical analyses were performed by unpaired two-tailed Student’s t-test, one-way analysis of variance (ANOVA) followed by Fisher’s PSLD post-hoc test and Pearson’s correlation method using Stat View for Macintosh version 5.0 software (Abacus Concepts, Inc., Berkeley, USA). The null hypothesis was rejected at \( p < 0.05 \).

**RESULTS**

Table 1 shows the clinical characteristics and baseline values of the BMD, bone markers, and serum lipids in the hypercholesterolemic patients and the control group. There were no significant differences in the age, years after menopause, BMI, systolic and diastolic blood pressure, fasting blood glucose, lumbar BMD, serum OC, urinary DPD, intact PTH, Ca or iP between the two groups.

The hypercholesterolemic patients who were on treatment with fluvastatin at 30 mg/day showed significant \( (p<0.001) \) reduction of the serum levels of TC and LDL-C from 251.9±14.7 and 163.2±15.8 mg/dl at baseline, respectively, to 196.0±14.9 mg/dl and to 113.9±13.6 mg/dl (−22.2% and −30.2%, respectively) at the end of the 36-month study period (Fig. 1). The serum HDL-C increased significantly \( (p<0.001) \) from 50.8±11.9 at base line to 65.0±11.5 mg/dl (27.9%) at the end of the 36-month study period in the fluvastatin-treated patients (Fig. 1). The serum non-HDL-C decreased significantly \( (p<0.001) \) from 201.1±12.6 at base line to 131.0±13.2 mg/dl (−34.8%) at the end of the 36-month study period.

No significant changes of the lipid profile were observed at any time-point during the study period.

---

**Table 1. Baseline characteristics of the study population**

| Characteristics               | Hypercholesterolic patients (n=28) | Control subjects (n=28) | \( p \) value |
|-------------------------------|-----------------------------------|------------------------|--------------|
| Age (years)                   | 64.0±3.6                          | 63.9±3.8               | n.s.         |
| Years after menopause         | 14.2±4.5                          | 14.4±4.2               | n.s.         |
| Body mass index (kg/m²)       | 22.4±1.9                          | 22.5±1.7               | n.s.         |
| Systolic blood pressure (mmHg)| 125.3±13.6                        | 123.5±14.8             | n.s.         |
| Diastolic blood pressure (mmHg)| 70.7±9.6                        | 73.0±10.8              | n.s.         |
| Total cholesterol (mg/dl)     | 251.9±14.7                        | 170.1±12.5             | <0.001       |
| Triglycerides (mg/dl)         | 88.4±13.6                         | 90.4±15.2              | n.s.         |
| LDL-cholesterol (mg/dl)       | 163.2±15.8                        | 106.0±12.3             | <0.001       |
| HDL-cholesterol (mg/dl)       | 50.8±11.9                         | 51.6±6.3               | n.s.         |
| Fasting blood glucose (mg/dl) | 89.2±14.3                         | 87.3±16.5              | n.s.         |
| Lumbar BMD (g/cm²)            | 0.589±0.078                       | 0.592±0.070            | n.s.         |
| Osteocalcin (ng/ml)           | 10.8±3.2                          | 10.8±3.1               | n.s.         |
| Urinary DPD (nM/mMCr)         | 10.0±3.1                          | 10.6±2.9               | n.s.         |
| intact PTH (pg/ml)            | 46.6±9.8                          | 46.8±9.9               | n.s.         |
| serum calcium (mg/dl)         | 9.2±0.5                           | 9.3±0.6                | n.s.         |
| serum iP (mg/dl)              | 3.5±0.5                           | 3.5±0.4                | n.s.         |

Values are expressed as mean±SD. LDL, serum low density lipoprotein; HDL, serum high-density lipoprotein; BMD, bone mineral density; DPD, deoxypyridinoline; iP, inorganic phosphate; n.s., not significant.
in the control group. Also, the serum levels of Ca, iP and intact PTH remained within their respective normal ranges in both the treated patients and the control group.

The mean BMD changes over the 3-year study period relative to the values at the baseline are shown in Fig. 2. In the fluvastatin-treated group BMD significant ($p<0.001$) increase of the BMD began to be noted from 6 months onward after the start of the study. On the other hand, significant decrease of the BMD ($p<0.001$) as compared with the value at baseline was observed in the control group at the time-points examined. The differences between the two groups remained statistically significant ($p<0.001$) throughout the study period (Fig. 2).

In patients treated with fluvastatin, no significant changes of the serum OC or u-DPD were observed at any time-point of examinations during the study period (Fig. 3). In control group, the serum OC began to decrease significantly ($p<0.001$) as compared with the values at baseline from 12 months onward, and the values continued to decrease thereafter until 36 months, or the end of the study periods (Fig. 3). In the same group, the u-DPD level remained significantly higher ($p<0.001$) as compared with the value at baseline throughout the study period. The difference between the treated patients and control subjects were statistically significant ($p<0.001$) at 12, 24 and 36 months for the serum OC, and at 6, 12, 24 and 36 month for the u-DPD (Fig. 3).

A significant negative correlation was found at 24 months between the changes in the spine BMD and the u-DPD in fluvastatin-treated group ($r=-0.405$, $p<0.05$) (Fig. 4).

**DISCUSSION**

According to the results of the present study, 3-year treatment with fluvastatin at 30 mg/day moderately increase bone formation and stability and thereby the BMD in postmenopausal hypercholesterolemic women. Although caution must be exercised in comparing the results obtained using different experimental models, these findings are consistent with the results of previous in vitro and animals studies that examined the influence of statins on the osteoblastic activity.$^{2-5}$ Namely, Mundy et al. conducted an in-depth study of the effects of statins on prenylation of GTPase proteins blocking the mevalonate pathway in osteoblast
recruitment and proliferation. In addition, Hana-
yama et al. demonstrated that fluvastatin signifi-
cantly attenuated osteoclast differentiation and acti-
vation through blockade of the classical mevalonate 
pathway and an antioxidant action, leading to pre-
vention of osteoporosis. To the best of our knowl-
edge, this is the first prospective study to investi-
gate the changes in both bone remodeling 
parameters and BMD in postmenopausal women 
treated with the usual clinical dose of fluvastatin. 

Although the 3-year treatment period used in 
this study might have been too short for precise 
evaluation of the longitudinal changes of the BMD 
by DXA, the favorable effects of statins on the BMD 
and bone formation observed in the fluvastatin-
treated subjects as compared with the changes in 

Fig. 2. Effect of fluvastatin on bone mineral density (BMD) in the lumbar spine of the central portion of lateral scout 
view of lumbar 2 to 4 vertebrae. Each value is expressed as mean±SD; fluvastatin treated group (●-●), 
\( n=28 \); controls (■-■) \( n=28 \); *** \( p<0.001 \) vs. baseline (paired t-test); ### \( p<0.001 \) vs. controls (ANOVA).

Fig. 3. Changes in the serum osteocalcin (OC) and urinary deoxypiridinoline (U-DPD) levels. mean±SD; 
fluvastatin treated group (●-●), \( n=28 \); controls (■-■) \( n=28 \); *** \( p<0.001 \) vs. baseline (paired 
test); ### \( p<0.001 \) vs. controls (ANOVA).
the control group could partially explain the fracture risk reduction observed in most retrospective studies\(^1\),\(^{13,38-41}\). Watanabe et al.\(^4\), in a clinical trial comparing the effects of fluvastatin and pravastatin, stated that OC and serum carboxyterminal telopeptide of collagen I and bone-ALP fell 24% after 26 weeks in subjects randomized to fluvastatin 20 mg/day, and fell 44% and 25%, respectively, in those who were randomized to fluvastatin 10 mg/day. Moreover, in our study, the tendency towards increase of the BMD in the fluvastatin-treated group was also accompanied by a decrease of the u-DPD, suggestive of a reduced osteoclastic activity. Our results seem to be inconsistent with those of previous studies, which have reported a reduction or no variation of the bone-ALP in patients treated with fluvastatin or simvastatin\(^2\),\(^{20,25,43}\). It is possible that the difference in the results between these previous studies and our own experience could be explained by the different age group of the subjects and use of different types and dosages of the statins between our studies.

With regard to bone formation, we did not find any change of serum OC levels in the fluvastatin-treated group as compared with that in the control group during the examination period in our study. These results seem in contrast with the data reported by other authors\(^2\),\(^6\),\(^\text{43}\), which demonstrated an influence of the statins, \textit{in vitro}, also on the osteoclastic activity. Likewise, longitudinal studies in humans have reported an inhibitory effect of the statins on the osteoblastic activity\(^2\),\(^\text{20,43}\). However, most of these data were obtained over shorter treatment periods than the 3-year treatment period employed in our study, and were obtained using different statins at different dosages, which has been reported to have differential effects on the activity of bone cells in rats\(^4\).

Although the number of patients in our study is limited, the findings of no significant changes of the serum OC or u-DPD in the fluvastatin-treated group as compared with that in the control group during the study period could suggest an imbalance between bone formation and resorption. These variations of the BMD have been reported to occur to lesser extent with simvastatin treatment in post-menopausal women\(^4\), as compared to those reported for the majority of antiresorptive drugs\(^4\),\(^\text{47}\). However, other drugs used for the treatment of osteoporosis, such as raloxifene\(^4\) and calcitonin\(^4\), have been reported to markedly reduce the risk of vertebral fractures in the face of a modest increase of the BMD, comparable to that observed with fluvastatin in the present study. Therefore, our longitudinal data could partially support the findings of previous retrospective studies reporting a reduced risk of fractures in dyslipidemic patients treated with statins. Both the stabilization/slight gain of the BMD and the favorable changes of bone turnover could positively influence the bone structure, enhancing the bone strength; however, this hypothesis needs to be verified by further and larger stud-

![Figure 4. Correlation between the changes of bone mineral density (BMD) and those of the urinary deoxypiridinoline (U-DPD) levels at month 24 in fluvastatin treated group.](image-url)

\(\tau = -0.405, p < 0.05\)

\(n = 28\).
ies. In conclusion, although our study may have been limited by the small size of the study population and the short period of follow-up, statins moderately induce bone formation, with a positive effect on the BMD. This finding could represent a useful step for carrying out further large-scale and randomized studies for evaluation of the possible role of statins in the treatment of osteoporosis.

REFERENCES

1. McFarlane SI, Muniyappa R, Francisco R, Sower JR. Pleiotropic effects of statins: lipid reduction and beyond. J Clin Endocrinol Metab, 87: 1451-1458, 2002.
2. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Zhao M, Gutierrez G. Stimulation of bone formation in vitro and in rodents by statin. Science, 286: 1946-1949, 1999.
3. Maeda T, Matsunuma A, Kawane T, Horiuchi N. Simvastatin promotes osteoblast differentiation and mineralization in MC3T3-E1 cells. Biochem Biophys Res Commun, 280: 874-877, 2001.
4. Ohnaka K, Shimoda S, Nawata H, Shimokawa H, Kaibuchi K, Iwamoto Y, Takayangi R. Pita-vastatin enhanced BMP-2 and osteocalcin expression by inhibition of Rho-associated kinase in human osteoblasts. Biochem Biophys Res Commun, 287: 688-692, 2000.
5. Sugiyama M, Kodama T, Konishi K, Abe K, Asami S, Oikawa S. Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein 2 in human osteosarccoma cells. Biochem Biophys Res Commun, 271: 688-692, 2000.
6. van Beeck E, Piterman E, Cohen L, Łowik C, Papapoulos S. Farnesyl pyrophosphate synthase is the molecular target of nitrogen — containing bisphosphonates. Biochem Biophys Res Commun, 264: 108-111, 1999.
7. Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ, Wesolowski G, Russell RGG, Rodan GA, Reszka AA. Alendronate mechanism of action: geranylgeraniol, an intermediates in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci USA, 96: 133-138, 1999.
8. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res, 13: 581-589, 1989.
9. Massy ZA, Keane WF, Kasiskie BL. Inhibition of the mevalinate pathway: benefits beyond cholesterol reduction. Lancet, 347: 102-103, 1996.
10. Reid IR, Hague WH, Emberson J, Baker J, Tonkin A, Hunt D, MacMahon S, Sharpe N, on behalf of the LIPID study group. Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomized controlled trial. Lancet, 357: 509-512, 2001.
11. van Staa TP, Wegman S, de Vries F, Leufkens B, Cooper C. Use of statins and risk of fractures. JAMA, 285: 1850-1855, 2001.
12. Lacroix AZ, Cauley JA, Pettinger M, Hsia J, Bauer DC, McGowan J, Chen Z, Lewis CF, Meneely G, Passaro MD, Jackson RD. Statin use, clinical fracture, and bone density in postmenopausal women: results from Women’s Health Initiative Observational Study. Ann Intern Med, 139: 97-104, 2003.
13. Wang PS, Solomon DH, Mogun H, Avorn J. HMG-CoA reductase inhibitors and risk of hip fractures in elderly patients. JAMA, 283: 3211-3216, 2000.
14. Chan KA, Andrade SE, Boles M, Buist DS, Chase GA, Donahue JG, Goodman MJ, Gurwit JH, LaCroix AZ, Platt R. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet, 335: 2185-2188, 2002.
15. Pasco J, Kotowicz M, Henry M, Sanders K, Nicholson G. Statin use, bone mineral density, and fracture risk: Geelong Osteoporosis Study. Arch Intern Med, 162: 537-540, 2002.
16. Bauer D, Mundy G, Jamal S, Black DM, Cauley JA, Ensrud KE, van der Klift M, Pols HA. Use of statins and fracture: results of four prospective studies and cumulative meta-analysis of observational studies and control trials. Arch Intern Med, 164: 146-152, 2004.
17. Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H. HMG-CoA reductase inhibitors and risk of fractures. JAMA, 283: 3205-3210, 2002.
18. Edwards CJ, Hart DJ, Spector TD. Oral statins and increased bone mineral density in postmenopausal women. Lancet, 355: 2218-2219, 2002.
19. Wada Y, Nakamura Y, Koshiyama H. Lack of positive correlation between statin use and bone mineral density in Japanese subjects with type 2 diabetes. Arch Intern Med, 160: 2865, 2000.
20. Bjarnason NH, Ris BJ, Christiansen C. The effect of fluvastatin on parameters of bone remodeling. Osteoporos Int, 12: 380-384, 2001.
21. Sirola J, Honkanen R, Kröger H, Juvelin JS, Mäenpää P, Saarikoski S. Relation of statin use and bone loss: a prospective population based cohort study in elderly postmenopausal women. Osteoporos Int, 13: 537-541, 2002.
22. Pasco JA, Kotowicz MA, Henry MJ, Sanders KM, Nicholson GC. Geelog osteoporosis study Statin use, bone mineral density, and fracture risk. Arch Intern Med, 162: 537-540, 2002.
23. Rejnmark L, Buus NH, Vestergaard P, Andreassen F, Larsen ML, Mosekilde L. Statins decrease bone turnover in postmenopausal women : a cross-section study. Eur J Clin Invest, 32: 581-589, 2002.
24. Chung YS, Lee MD, Lee SK, Kim HM, Fitzpatrick LA. HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients. J Clin Endocrinol Metab, 85: 1137-1142, 2000.
25. Chan MH, Mak WL, Chiu RW, Chow CC, Chan IS, Lam CK. Simvastatin increases serum osteocalcin concentration in patients treated for hypercholesterolemia. J Clin Endocrinol Metab, 86: 4556-4559, 2001.
26. Stein EA, Farnier M, Waldstreicher J, Mercuri M. Effects of statins on biomarkers of bone metabolism: a randomized trial. Nutr Metab Cardiovasc Dis, 11: 84-87, 2001.
27. Mostaza JM, De la Piedra C, Curiel MD, Pena R, Lahoz C. Pravastatin therapy increase procollagen I N-terminal propeptide. Clin Chim Acta, 308: 133-137, 2001.
28. Staal A, Frith JC, French MH, Swartz J, Harrity TW, Tamasi J, Rogers MJ, Feyen JH. The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA-reductase activity. J Bone Miner Res, 18: 88-96, 2003.
29. Bauer DC. HMG-CoA reductase inhibitors and the skeleton: a comprehensive review. Osteoporos Int, 14: 273-282, 2003.
30. Tang QO, Tran GT, Gamie Z, Graham S, Tawalaikorn S, Wattanasirichaigoon S, Kaufman L. Effects of statin vs. non-statin lipid-lowering therapy on bone formation and bone mineral density biomarkers in patients with hyperlipidemia. Bone, 46: 1011-1015, 2010.
31. Watanabe S, Fukumoto S, Takeuchi Y, Fujita H, Nakano T, Fujita T. Effects of 1-year treatment with fluvastatin or pravastatin on bone. Am J Med, 110: 584-587, 2001.
32. Stein EA, Farnier M, Waldstreicher J, Mercuri M, on behalf of the simvastatin/atrovastatin study group. Effects of statins on biomarker of bone metabolism: a randomized trial. Nutr Metab Cardiovasc Dis, 11: 84-87, 2001.
33. Maritz FJ, Conradie MM, Hulley PA, Hough FS. The effects of simvastatin treatment on bone mineral density and quantitative bone histomorphometry in rodents. Osteoporosis Int, 13: S12 (Abstract), 2002.
34. Montagnani A, Gonnelli S, Cepollaro C, Pacini MS, Campagna MB, Franci B, Lucani B, Gennai C. Effect of simvastatin treatment on bone mineral density and bone turnover in hypercholesterolemic postmenopausal women: a 1-year longitudinal study. Bone, 32: 427-433, 2003.
46. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer C, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE, for the fracture intervention trial research group. Randomized trials of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet, 348: 1535-1541, 1996.

47. Reginster JY, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R, On behalf of the vertebral efficacy with risedronate therapy (VERT) study group. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporosis Int, 11: 83-91, 2002.

48. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Glüer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR, For the multiple outcomes of raloxifene evaluation (MORE) investigators. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA, 282: 637-645, 1999.

49. Chesnut CH 3rd, Silvermen S, Andriano K, Genant H, Gimona A, Harris S, Kiel D, LeBoff M, Maricic M, Miller P, Moniz C, Peacock M, Richardson P, Watts N, Baylink D, for the PROOF study group. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. Am J Med, 109: 267-276, 2000.